Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Dermatology Immune Disorders Companies

MedImmune signs deal with SBI Biotech

This article was originally published in Scrip

Executive Summary

MedImmunehas signed a licensing agreement with SBI Biotechto develop and commercialise the Japanese company's anti-ILT7 protein for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. SBI will receive an up-front payment as well as milestone payments and royalties on future marketed products. MedImmune has the rights to any resulting product candidates and will be responsible for preclinical and clinical development. It will also have the option to license additional targets resulting from SBI's research activities. Dave Mott, MedImmune's ex-CEO who left the company last July, has joined New Enterprise Associates, a venture capital firm active in the biotechnology field.

Table

View full table

Topics

Tags:
Dermatology Immune Disorders Companies
Latest Headlines

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

See All
UsernamePublicRestriction

Register

SC025767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By